ARTICLE | Company News
China Medical Systems licenses Traumakine from Faron
May 21, 2015 1:56 AM UTC
China Medical Systems Holding Ltd. (HKSE:867) licensed rights in greater China to develop and commercialize Traumakine ( FP-1201) from Faron Pharmaceuticals Ltd. (Turku, Finland). This year, Faron expects to start a European Phase III study of the recombinant human interferon (IFN) beta-1a to treat severe and acute respiratory distress syndrome (ARDS).
Faron received a EUR 5 million ($5.7 million) equity investment from A&B Ltd., a Hong Kong investment firm owned by CMS Chairman and CEO Kong Lam. CMS's Huaizheng Peng joined Faron's board. ...